Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epithelial-Specific Methylation Marker A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer

Epithelial-Specific Methylation Marker A Potential Plasma Biomarker in Advanced Non-small Cell... ORIGINAL ARTICLE Epithelial-Specific Methylation Marker A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer Chanida Vinayanuwattikun, MD,*† Virote Sriuranpong, MD, PhD,† Suebpong Tanasanvimon, MD,† Poonchavist Chantranuwat, MD,‡ and Apiwat Mutirangura, MD, PhD§ used to develop risk-adaptive treatments for patients with lung Background: Under physiological conditions, leukocytes contrib- cancer. ute the majority of circulating DNA in plasma. Therefore, detection Key Words: SHP-1, Methylation, Biomarker, Lung cancer, Epithe- of methylation at the SHP-1 promoter 2 (SHP1P2) in plasma, which lial-specific methylation marker. represents epithelial tumor-derived circulating nucleic acids, may serve as a potential noninvasive biomarker for non-small cell lung (J Thorac Oncol. 2011;6: 1818–1825) cancer (NSCLC). Materials and Method: A quantitative polymerase chain reaction- based assay was used to determine the level of SHP1P2 methylation ecent studies have indicated that extracellular, freely cir- in plasma. Blood samples were prospectively collected from 58 Rculating nucleic acids in plasma and serum (CNAPS) are patients with advanced NSCLC, 20 patients with early NSCLC, and a valuable biomarker that can be used to detect the presence 52 healthy volunteers. of several diseases, such as cancer, cardiovascular disease, Results: Most of the healthy volunteers exhibited undetectable pulmonary thromboembolism, connective tissue disease, in- levels of SHP1P2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Epithelial-Specific Methylation Marker A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer

Journal of Thoracic Oncology , Volume 6 (11) – Nov 1, 2011

Loading next page...
 
/lp/wolters-kluwer-health/epithelial-specific-methylation-marker-a-potential-plasma-biomarker-in-brB542ow1l

References (28)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318226b46f
pmid
21964525
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Epithelial-Specific Methylation Marker A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer Chanida Vinayanuwattikun, MD,*† Virote Sriuranpong, MD, PhD,† Suebpong Tanasanvimon, MD,† Poonchavist Chantranuwat, MD,‡ and Apiwat Mutirangura, MD, PhD§ used to develop risk-adaptive treatments for patients with lung Background: Under physiological conditions, leukocytes contrib- cancer. ute the majority of circulating DNA in plasma. Therefore, detection Key Words: SHP-1, Methylation, Biomarker, Lung cancer, Epithe- of methylation at the SHP-1 promoter 2 (SHP1P2) in plasma, which lial-specific methylation marker. represents epithelial tumor-derived circulating nucleic acids, may serve as a potential noninvasive biomarker for non-small cell lung (J Thorac Oncol. 2011;6: 1818–1825) cancer (NSCLC). Materials and Method: A quantitative polymerase chain reaction- based assay was used to determine the level of SHP1P2 methylation ecent studies have indicated that extracellular, freely cir- in plasma. Blood samples were prospectively collected from 58 Rculating nucleic acids in plasma and serum (CNAPS) are patients with advanced NSCLC, 20 patients with early NSCLC, and a valuable biomarker that can be used to detect the presence 52 healthy volunteers. of several diseases, such as cancer, cardiovascular disease, Results: Most of the healthy volunteers exhibited undetectable pulmonary thromboembolism, connective tissue disease, in- levels of SHP1P2

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Nov 1, 2011

There are no references for this article.